{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:17:58Z","timestamp":1778879878934,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:33:11Z","timestamp":1774297991000},"page":"435-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Population"],"prefix":"10.1016","volume":"30","author":[{"given":"Janus P.","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasmik","family":"Ghazinyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Wai-Sun Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatol Baltim Md"},{"issue":"8","key":"10.1016\/j.cld.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","article-title":"Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ha","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ajg.2015.235","article-title":"Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy","volume":"110","author":"Wei","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.cld.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00535-016-1264-3","article-title":"Nonalcoholic fatty liver disease in Asia: emerging perspectives","volume":"52","author":"Seto","year":"2017","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cld.2023.01.011","article-title":"Special population: lean nonalcoholic fatty liver disease","volume":"27","author":"Duseja","year":"2023","journal-title":"Clin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4093\/dmj.2024.0541","article-title":"Metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: a review and position statement of the fatty liver research group of the Korean diabetes association","volume":"48","author":"Bae","year":"2024","journal-title":"Diabetes Metab J"},{"issue":"2","key":"10.1016\/j.cld.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jhep.2023.07.031","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD","volume":"80","author":"De","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi","year":"2019","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.006_bib18","first-page":"149","article-title":"Association of genetic variations with NAFLD in lean individuals","volume":"42","author":"Lin","year":"2022","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jgh.12996","article-title":"Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: a case-control study","volume":"30","author":"Ha","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc10-0606","article-title":"Sagittal abdominal diameter is a strong anthropometric measure of visceral adipose tissue in the Asian general population","volume":"33","author":"Yim","year":"2010","journal-title":"Diabetes Care"},{"issue":"48","key":"10.1016\/j.cld.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"18273","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.cld.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid","year":"2009","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3390\/nu15102335","article-title":"Sex, nutrition, and NAFLD: relevance of environmental pollution","volume":"15","author":"Dolce","year":"2023","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.numecd.2017.10.014","article-title":"Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study","volume":"28","author":"Duarte","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"10.1016\/j.cld.2026.01.006_bib27","article-title":"Altered fecal microbiota correlates with liver biochemistry in Nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/00365521.2014.983160","article-title":"Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels","volume":"50","author":"Akyuz","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatol Baltim Md"},{"issue":"12","key":"10.1016\/j.cld.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.cgh.2019.09.027","article-title":"Performance of simple fibrosis scores in Nonobese patients with nonalcoholic fatty liver disease","volume":"18","author":"Fu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MEG.0000000000001946","article-title":"Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly Obese individuals","volume":"34","author":"Eren","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14309\/ctg.0000000000000042","article-title":"Role of fatty liver index and metabolic factors in the prediction of nonalcoholic fatty liver disease in a lean population receiving health checkup","volume":"10","author":"Hsu","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41366-021-00881-8","article-title":"Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity","volume":"45","author":"Drolz","year":"2021","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.cld.2026.01.006_bib35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatol Baltim Md"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib38","article-title":"Diagnosis and management of lean metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review","volume":"16","author":"Njei","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.cld.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.14112","article-title":"Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients","volume":"46","author":"Sookoian","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.cld.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1440-1746.2012.07165.x","article-title":"Exercise and diet modification in Non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors","volume":"27","author":"Jin","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"issue":"1S Suppl 1","key":"10.1016\/j.cld.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (Dysfunction)-associated fatty liver disease in individuals of normal weight","volume":"19","author":"Eslam","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.ijo.0803761","article-title":"Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review","volume":"32","author":"Chaston","year":"2008","journal-title":"Int J Obes"},{"issue":"10","key":"10.1016\/j.cld.2026.01.006_bib45","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/MEG.0000000000001656","article-title":"Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients","volume":"32","author":"Hamurcu Varol","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.006_bib47","article-title":"Lean nonalcoholic fatty liver disease and sarcopenia","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.006_bib48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/nu17010178","article-title":"Sarcopenia in MASLD-eat to beat steatosis, move to prove strength","volume":"17","author":"Cri\u015fan","year":"2025","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.cld.2026.01.006_bib49","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.006_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primer"},{"issue":"6","key":"10.1016\/j.cld.2026.01.006_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cld.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cld.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.cld.2026.01.006_bib54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:59:14Z","timestamp":1778878754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000061"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.006","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special Population","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}